In this issue:
DNA mutation concordance in primary tumour and cell-free DNA
Prostate cancer screening using riskprediction, MRI, and targeted biopsies
Talazoparib monotherapy in mCRPC with DNA repair alterations
Short ADT and RT dose escalation in prostate cancer
RT + ADT + docetaxel for nonmetastatic unfavourable-risk prostate cancer
Docetaxel + enzalutamide for mCRPC
Adjuvant low-dose statin use after radical prostatectomy
Atezolizumab + radium-223 dichloride for mCRPC
High-dose salvage RT + ADT in oligorecurrent pelvic node relapse
Factors associated with discontinuation of active surveillance
Please login below to download this issue (PDF)